Delivery Order SPE2DB22D1106-SPE2DB25FFGP6
- Not listed
- On August 28, 2025, the Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HyperRab 300 Unit/mL Vial 5mL with a ceiling value of $1,790.80 and an ultimate completion date of September 19, 2025. This non-set-aside, firm fixed price delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The product will...
- The Defense Logistics Agency awarded a $16,632.48 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HYPERRAB 300 Unit/ML Vial medication. This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for HYPERRAB 300 Unit/mL, a rabies immunoglobulin product, with a ceiling value of $18,711.54. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under a child contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,744.80 on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL vials (5mL) to support federal medical procurement needs. The award is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 20, 2025, and is funded through the Defense Logistics Agency's Medical Supply Chain division. This contract represents...
- This delivery order, awarded August 14, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of HYPERRAB 300 unit/mL vials (5 mL), a rabies immunoglobulin product critical for post-exposure prophylaxis in military and federal healthcare settings. The contract is valued at $1,790.80 with a firm fixed price structure and an ultimate completion date of September 5, 2025. The award was made through competitive procurement with no set-aside designation....
- The Defense Logistics Agency issued a delivery order valued at $3,465.10 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This non-set-aside, firm fixed-price delivery order was awarded on July 23, 2025, with an ultimate completion date of August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. HYPERRAB is a rabies immunoglobulin (human) product used for post-exposure prophylaxis and...
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- This delivery order, issued on August 1, 2025, awards AmerisourceBergen Drug Corp $4,851.14 for supply of HYPERRAB 300 units/ml under a firm fixed-price contract with an ultimate completion date of August 22, 2025. The contract, which is not set-aside and competitively awarded, is funded by the Defense Logistics Agency's Medical Supply Chain division and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin product used for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product commonly used for post-exposure prophylaxis. This firm fixed price delivery order, valued at $10,744.80, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 through December 2026. The contract was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside, firm fixed-price delivery order carries a ceiling value of $21,489.60 and is scheduled for completion by September 29, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFGP6Delivery Order
On September 3, 2025, the Defense Logistics Agency awarded a delivery order valued at $4,851.14 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This firm fixed-price delivery order, with an ultimate completion date of September 24, 2025, represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin product used for post-exposure prophylaxis in rabies prevention, critical for military and federal healthcare system readiness. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The prime indefinite delivery vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply specialty medications, generic drugs, vaccines, and related medical commodities to support military healthcare programs worldwide. Through this flexible contract structure, the company provides essential pharmaceutical products to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 9/3/25 |